Ketones and inborn errors of metabolism: old friends revisited
Arch Pediatr Adolesc Med 161:356361 Wingate M, Kirby RS, Pettygrove S, Cunniff C, Schulz E, Ghosh T, Robinson C, Lee LC, Landa R, Constantino J, Fitzgerald R, Zahorodny W, Daniels J, Nicholas J, Charles J, McMahon W, Bilder D, Durkin M, Baio J, Christensen D, Braun KV, Clayton H, Goodman A, Doernberg N, Yeargin-Allsopp M, Lott E, Mancilla KC, Hudson A, Kast K, Jolly K, Chang A, Harrington R, Fitzgerald R, Shenouda J, Bell P, Kingsbury C, Bakian R, Henderson A, Arenson C, Washington A, Frenkel G, Wright V (2014) Prevalence of autism spectrum disorder among children aged 8 years autism and developmental disabilities monitoring network, 11 sites, United States, 20 I 0
2013 Aug;9(2):1325
5 Targeted therapies for MG In recent years, targeting MG metabolism by developing MG scavengers and GLO1 modulators has emerged as a promising strategy for cancer therapy
Sodiumglucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) both improve cardiovascular outcomes, but their comparative roles in HF and the potential value of combination therapy remain uncertain
The net effect of increased hypothalamic malonyl-CoA binding to CPT1C is, therefore, satiety and appetite suppression
